Meeting
2017 ASCO Annual Meeting
Risk-adapted therapy utilizing upfront brentuximab vedotin (Bv) and rituximab (R) with reduced toxicity chemotherapy in children, adolescents, and young adults with Hodgkin lymphoma.
Authors
Jessica Hochberg
New York Medical College, Valhalla, NY
Jessica Hochberg , Liana Klejmont , Lauren Harrison , Allyson Flower , Quihu Shi , Jaclyn Basso , Mitchell S. Cairo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT02398240
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10532)
DOI
10.1200/JCO.2017.35.15_suppl.10532
Abstract #
10532
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
First Author: Christine Mauz-Körholz
Poster
2018 ASCO Annual Meeting
KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.
First Author: Christine Mauz-Korholz
Poster
2022 ASCO Annual Meeting
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.
First Author: Jane N. Winter
Poster
2021 ASCO Annual Meeting
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.
First Author: Howland E. Crosswell